Consideration on Pharmacovigilance Curriculum in Medical and Pharmaceutical Colleges

Abstract

Abstract: Pharmacovigilance has extended from adverse drug reaction to the lifecycle of product. Practitioners in medicine are not familiar with pharmacovigilance in China now. Medical and pharmaceutical colleges, as the institute for training professionals, have the advantage to set up the curriculum of pharmacovigilance, teach knowledge relevant to pharmacovigilance, and promote the development of pharmacovigilance in China. In this article, we analyzed the necessity of setting this curriculum, difficulties and countermeasures, and other issues in the process. In the end, we suggest relevant colleges set the pharmacovigilance curriculum in the form of elective courses.

Key words: pharmacovigilance, adverse drug reaction, curriculum

YE Xiao-fei, XU Jin-fang, GUO Xiao-jing, HE Jia. Consideration on Pharmacovigilance Curriculum in Medical and Pharmaceutical Colleges[J]. Chinese Journal of Pharmacovigilance, 2012, 9(10): 598-600.

References

[1] 范燕,陈易新,闫占军.刍议药物警戒与药品风险管理[J].药物流行病学杂志, 2009,18(4):223-226.
[2] 孙钰.药物警戒的起源、发展与展望[J].药物流行病学杂志,2010,19(8):455-461.
[3] UMC Pharmacovigilance Training Course[EB/OL]. http://who-umc.
org/DynPage.aspx?id=116849&mn1=7347&mn2=7252&mn3=7323
4 &mn4=7632.
[4] Houming Xu, Yue Wang, Naifeng Liu. A hospital-based survey of healthcare professionals in the awareness of pharmacovigilance[J]. Pharmacoepidemiology and drug safety 2009;18(7):624-630.
[5] Changhai Su, Hui Ji, Yixin Su. Hospital pharmacists’ knowledge and opinions regarding adverse drug reaction reporting in Northern China[J].Pharmacoepidemiology and drug safety 2010;19(3):217-222.
[6] 陈文,李永昌,傅政,等. 2003-2007年上海市药品不良反应报告表质量分析[J].药学服务与研究2008;8(4):276-280.
[7] 叶小飞,钱维,贺佳. 药品不良反应信号检测中的Meta分析[J].中国药物警戒,2010;7(3):148-150.
[8] 叶小飞,王海南,陈文,等. 数据挖掘在药物警戒中的应用[J].中国药物警戒,2008;5(1):36-40.
[9] 王晓瑜,杜文民,王宏敏,等.药品不良反应报告中存在的问题及改进建议[J].上海医药, 2006,27(5): 215-216.
[10] 周文.药物流行病学[M].第1版.人民卫生出版社,2007．
[11] Ronald D. Mann, Elizabeth B. Andrews. Pharmacovigilance (second edition) [M]. John Wiley & Sons,2007.
[12] Brian L. Storm, Stephen E. Kimmel. Textbook of pharmacoepidemiology [M].John Wiley & Sons,2006.
[13] Brian L.Storm. Pharmacoepidemiology(fourth edition)[M].John Wiley & Sons,2005.
[14] 董卫,杜文民,William A Blumentals,等.加强政府、企业和学术界合作,促进我国药物流行病学的发展[J].药物流行病学杂志,2011;20(1):6-10.

[1]	JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166.
[2]	LI Yingfen, HAN Lei. Analysis of 319 cases of adverse drug reaction induced by cerebroprotein hydrolysate for injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 195-198.
[3]	XU Weijia, PENG Qi, HUANG Haiyu, ZHANG Leijiao, XIAO Hua, WU Xue. 285 cases of adverse drug reaction related to new antineoplastic drugs [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 199-203.
[4]	GUO Qinghua, PENG Xiaoxiao, ZHU Ping, LIU Xilin, YANG Yinghua, CHEN Zhihai. One case of multiple organ dysfunction syndrome caused by amlodipine overdose [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 204-207.
[5]	FANG Meilin, ZHENG Huimin, WANG Cunze, WANG Ling, RUAN Junshan. One case of generalized myalgia caused by oxaliplatin [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 208-210.
[6]	CHEN Yuyan, ZHANG Mingxia, ZHANG Tao, ZHANG Jin. One case of interstitial pneumonia caused by serplulimab injection [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 213-215.
[7]	CAO Guiping, DENG Linlin, ZHU Ganhong, LU Ying, MA Shuang, CHEN Linlin, Liu Lili. One case of severe liver injury caused by Tianma Shouwu tablets [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 216-218.
[8]	GUO Longxin, GAO Yunjuan, WU Chengzhao, LONG Minjuan, ZHU Shengkai, SONG Haibo, ZHAO Xu, XIAO Xiaohe. Exploring new risk signals and susceptibility factors of traditional Chinese medicine-induced hepatotoxicity based on big data from adverse reaction monitoring [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 15-19.
[9]	LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
[10]	JIANG Wenshuo, YANG Li. Adverse drug reaction among 694 patients in an epilepsy physician-pharmacist joint clinic [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 102-106.
[11]	CHEN Huayan, JIANG Dongbo, GUO Chunlian, YANG Jiaqi, LI Yuxin, CAI Weiming. Safety of nirmatrelvir/ritonavir in the treatment of novel coronavirus infections [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 107-110.
[12]	XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
[13]	LIU Saiyue, LYU Xiaoqin, ZHOU Yun. Key points of investigation and report of suspected death of adverse drug reaction [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 971-974.
[14]	LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977.
[15]	PANG Yu, LIU Bo, LYU Shaoli, WANG Tao, XING Ying, QIN Xingyu, TIAN Yuejie, WU Wenyu. Exploring the significance of collecting patient reports based on international pharmacovigilance experience [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 978-981.